U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON (Reuters) - Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.